Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis

Tetra Bio-Pharma IncNovember 22, 2018

ORLEANS, Ontario, Nov. 22, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market on its strategic partnership with Sirius Air Solutions Inc. (previously known as AES) to secure a source of supply for a specialized cannabis smoke air purifying system and a mask designed for law and emergency responders.

The parties are establishing a strategic alliance to develop a medical grade air purifier and mask that will address Health Canada, labour unions and public safety concerns surrounding exposure to the second-hand smoke of cannabis.

Tetra Bio-Pharma expects orders for the mask and air purifier from caregivers, medical institutions, law enforcement agencies and security services around the world.

“This technology will enable the consumers of a smokable cannabis product to take their medication in the privacy of their home or in a medical clinic while being cared for by their families, caregivers or medical personnel,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We have begun working with law enforcement representatives across the country to design a specialized mask that will alleviate the effects of second-hand smoke from cannabis while performing their duties.”

About Sirius Air Solutions Inc.Sirius Air Solutions Inc. (SAS) is an ultra-specialized air cleaner and smoke extractor manufacturer aiming to provide efficient answers for the most demanding innovative markets. Moreover, we are specialized in particle ultra filtration of air as well as in the chemical air filtration for contaminants present in gaseous form. Our approach is based on a deep understanding of airborne contaminants in order to design unique devices that consistently strive to exceed the highest standards available to date. Every day, we challenge ourselves to offer the most effective solutions to meet the most demanding situations that are proposed.

About Tetra Bio-Pharma Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statementsSome statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of the products mentioned above and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.